The estimated Net Worth of David J Woodhouse is at least $2.12 Million dollars as of 29 December 2021. Mr. Woodhouse owns over 17,654 units of Ngm Biopharmaceuticals Inc stock worth over $27,187 and over the last 5 years he sold NGM stock worth over $0. In addition, he makes $2,092,150 as Chief Executive Officer and Director at Ngm Biopharmaceuticals Inc.
Sign up
Mr. Woodhouse NGM stock SEC Form 4 insiders trading
David has made over 2 trades of the Ngm Biopharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 17,654 units of NGM stock worth $138,054 on 29 December 2021.
The largest trade he's ever made was exercising 17,654 units of Ngm Biopharmaceuticals Inc stock on 29 December 2021 worth over $138,054. On average, David trades about 3,628 units every 5 days since 2020. As of 29 December 2021 he still owns at least 17,654 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Mr. Woodhouse stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Woodhouse biography
David J. Woodhouse Ph.D. has been appointed as Chief Executive Officer, Director of the Company effective 7/13/2020. Mr. Woodhouse became our Chief Executive Officer, Acting Chief Financial Officer and a member of our Board of Directors in September 2018, after having served as our Chief Financial Officer from March 2015 until September 2018. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a managing director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.
What is the salary of David Woodhouse?
As the Chief Executive Officer and Director of Ngm Biopharmaceuticals Inc, the total compensation of David Woodhouse at Ngm Biopharmaceuticals Inc is $2,092,150. There are no executives at Ngm Biopharmaceuticals Inc getting paid more.
How old is David Woodhouse?
David Woodhouse is 50, he's been the Chief Executive Officer and Director of Ngm Biopharmaceuticals Inc since 2020. There are 13 older and 4 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
What's David Woodhouse's mailing address?
David's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Ngm Biopharmaceuticals Inc
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
What does Ngm Biopharmaceuticals Inc do?
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
What does Ngm Biopharmaceuticals Inc's logo look like?
Complete history of Mr. Woodhouse stock trades at Ngm Biopharmaceuticals Inc
Ngm Biopharmaceuticals Inc executives and stock owners
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Woodhouse,
Chief Executive Officer, Director -
Jin-Long Chen,
Founder, Chief Scientific Officer, Director -
William Rieflin,
Executive Chairman of the Board of Directors -
Suzanne Hooper,
Independent Director -
Dr. David J. Woodhouse Ph.D.,
CEO & Director -
Dr. Jin-Long Chen Ph.D.,
Founder, Chief Scientific Officer & Director -
Shelly Guyer,
Independent Director -
Siobhan Nolan Mangini,
CFO and Principal Financial & Accounting Officer -
McHenry Tichenor,
Independent Director -
David Goeddel,
Lead independent director -
David Schnell,
Independent Director -
Mark Leschly,
Independent Director -
William J. Rieflin J.D.,
Exec. Chairman of Directors -
Siobhan Mangini,
Chief Financial Officer -
Carole Ho,
Independent Director -
Hsiao Lieu,
Senior Vice President, Chief Medical Officer -
Marc Learned,
Vice President - Research Operations -
Hui Tian,
Senior Vice President - Research -
Wenyan Shen,
Senior Vice President - Biologics and CMC -
Alex DePaoli,
Senior Vice President, Chief Translational Officer -
Valerie Pierce,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Hsiao Dee Lieu,
Chief Medical Officer & Sr. VP -
Brian Muma,
VP of HR -
Valerie L. Pierce J.D.,
Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Alexander Duke Schwartz,
Exec. Director of Investor Relations -
Group L Ptcg Opportunity Ii...,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Gp, L...,
-
Group L P Svennilson Peter ...,
-
Peter Svennilson,
Director -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Iii, ...,
-
Aetna Wun Trombley,
President & COO -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Ii, L...,
-
Group L P Ponoi Capital Ii,...,
-
Group L Pcolumn Group Iii, ...,
-
Roger M Perlmutter,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Jean Frederic Viret,
Chief Financial Officer -
Group Gp, Lpcolumn Group Ii...,
-
Opportunity Iii Gp, Llc Tcg,
10% owner -
Irene Perlich,
Principal Accounting Officer